Thermo Fisher Scientific
Mass spectrometry plays a key role in the translational proteomics pipeline: whereas continuous improvements in technologies at the discovery side increase qualitative and quantitative coverage of the entire proteoform diversity, ongoing optimization of methodologies at the clinical diagnostic site improve analytical quality and standardization. Integrating both ends would streamline the discovery of new biomarkers by increased analytical quality, and revolutionize clinical diagnostic assays by adoption of multi-protein strategies, including isoforms and post-translational modifications.
In this presentation Irene van den Broek PhD, Advanced Clinical Biosystems Research Institute at Cedars-Sinai Medical Center, will show both the potential of multiplexed multiple reaction monitoring MS to fulfill the quality requirements for clinical application as well as discuss challenges and potential strategies for clinical application of data-independent acquisition MS as a tool to quantify and identify myofilament proteoforms in heart biopsies.
For research use only. Not for use in diagnostic procedures.
Irene van den Broek is a post-doctoral researcher at the Advanced Clinical Biosystems Research Institute, led by Dr. Jennifer van Eyk, at Cedars-Sinai Medical Center in Los Angeles. Her research has focused on the development and validation of clinical mass spectrometry methods for accurate quantification of proteins in complex matrices. Van Eyk’s lab has specialized in the development of robust technological pipelines for 100s of samples to precisely quantify 1000s of proteins, isoforms, and their post-translational modifications in disease pathways. Their research goal is to change medicine through development, optimization and adaption of proteomic technologies.
* Required field